it's just permanent now.

We are in our oncology era where, you know, I was seeing a statistic.

There's over 250 new drugs that have been approved in our space, right, in the last 20 years or so.

And that's remarkable.

And we've still got work to do.

But what we're also finding is this equilibrium between the challenge of being availability of interventions and accessibility of those interventions.

We really reached this inflection point where we have to think about both.

And does that mean we change drastically medical school, fellowship structure, different CMEs for oncologists?

What are some of the major milestones you see that we've achieved over that time?

Yeah, 40 years is pretty remarkable as we think about it.

Started in 1985.

I would, you know, really center around the number 40 actually for a lot of the great accomplishments.

Breast cancer mortality has reduced by over 40% over that period of time.

In addition, we've now reduced the age of which we recommend starting mammograms, now down to the age of 40.

In addition, we're starting to see other areas of disparities and gaps closing as well.

And to that point, Arif, sticking with you, where do some of the main challenges still remain?